FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. [electronic resource]
Producer: 20100721Description: 282-8 p. digitalISSN:- 1423-0232
- Adult
- Aged
- Antigens, CD34 -- biosynthesis
- Benzylamines
- Clinical Trials as Topic
- Cyclams
- Female
- Granulocyte Colony-Stimulating Factor -- administration & dosage
- Hematopoietic Stem Cell Mobilization -- methods
- Heterocyclic Compounds -- administration & dosage
- Humans
- Lymphoma, Non-Hodgkin -- therapy
- Male
- Middle Aged
- Multicenter Studies as Topic
- Multiple Myeloma -- drug therapy
- Placebos
- Product Surveillance, Postmarketing
- Randomized Controlled Trials as Topic
- Receptors, CXCR4 -- metabolism
- United States
- United States Food and Drug Administration
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.